EMA Withdrawn: Picato (Ingenol mebutate) — LEO Laboratories Ltd.

View source ↗

Summary

EMA has withdrawn Picato (ingenol mebutate) from the market in Europe.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis
• Keratosis Actinic

Drugs mentioned

• Picato (ingenol mebutate)

Snippet

Status: Withdrawn. Therapeutic area: Keratosis, Actinic. MAH: LEO Laboratories Ltd.. Decision date: 02/07/2020